JP2019510812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510812A5 JP2019510812A5 JP2018563747A JP2018563747A JP2019510812A5 JP 2019510812 A5 JP2019510812 A5 JP 2019510812A5 JP 2018563747 A JP2018563747 A JP 2018563747A JP 2018563747 A JP2018563747 A JP 2018563747A JP 2019510812 A5 JP2019510812 A5 JP 2019510812A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- antibody
- polypeptide
- bdm
- molecule according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 101150099985 bdm gene Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078237A JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A JP2024026531A (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900708 | 2016-02-26 | ||
| AU2016900709 | 2016-02-26 | ||
| AU2016900708A AU2016900708A0 (en) | 2016-02-26 | Multi-specific molecules 1 | |
| AU2016900709A AU2016900709A0 (en) | 2016-02-26 | Multi-specific molecules 2 | |
| PCT/AU2017/050168 WO2017143406A1 (en) | 2016-02-26 | 2017-02-27 | Multi-specific molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078237A Division JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510812A JP2019510812A (ja) | 2019-04-18 |
| JP2019510812A5 true JP2019510812A5 (enExample) | 2020-04-09 |
| JP7536424B2 JP7536424B2 (ja) | 2024-08-20 |
Family
ID=59685848
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563747A Active JP7536424B2 (ja) | 2016-02-26 | 2017-02-27 | 多重特異性分子 |
| JP2022078237A Pending JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A Pending JP2024026531A (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078237A Pending JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A Pending JP2024026531A (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190338013A1 (enExample) |
| EP (1) | EP3419667A4 (enExample) |
| JP (3) | JP7536424B2 (enExample) |
| CN (1) | CN109310766A (enExample) |
| AU (2) | AU2017222700B2 (enExample) |
| TW (1) | TW201734037A (enExample) |
| WO (1) | WO2017143406A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190338013A1 (en) * | 2016-02-26 | 2019-11-07 | Imunexus Pty Ltd | Multi-Specific Molecules |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| KR20200037388A (ko) * | 2017-08-16 | 2020-04-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질 |
| AU2018396970B2 (en) | 2017-12-28 | 2025-09-25 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
| KR20200118423A (ko) * | 2018-01-08 | 2020-10-15 | 난징 레전드 바이오테크 씨오., 엘티디. | 다중특이성 항원 결합 단백질 및 이의 사용 방법 |
| CN111699200B (zh) | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| KR20210141447A (ko) | 2018-12-26 | 2021-11-23 | 실리오 디벨럽먼트, 인크. | 항-ctla4 항체 및 이의 사용 방법 |
| JP2022520978A (ja) * | 2019-02-18 | 2022-04-04 | クーリエ セラピューティクス インコーポレイテッド | オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質 |
| WO2020198353A1 (en) * | 2019-03-26 | 2020-10-01 | Forty Seven, Inc. | Multispecific agents for treatment of cancer |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| KR20220130692A (ko) * | 2020-01-20 | 2022-09-27 | 우시 바이올로직스 아일랜드 리미티드 | 친화성 크로마토그래피를 위한 신규한 세척 완충제 용액 |
| EP3904378A1 (en) * | 2020-04-29 | 2021-11-03 | Hober Biotech AB | Bispecific protein |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| CN116648459A (zh) * | 2020-10-12 | 2023-08-25 | 格雷菲克斯公司 | 靶向响应SARS-CoV蛋白表达细胞的T细胞的抗体构建体、其设计和用途 |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| JP2024510291A (ja) * | 2021-03-16 | 2024-03-06 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫疾患を治療するための二機能性分子 |
| AU2022399232A1 (en) * | 2021-11-26 | 2024-07-04 | Imunexus Therapeutics Limited | Binding domain molecules on cell surfaces |
| CN115078718B (zh) * | 2022-07-22 | 2024-11-12 | 福建师范大学 | 一种基于表面增强拉曼技术检测透明质酸酶的方法 |
| WO2024102190A2 (en) * | 2022-11-09 | 2024-05-16 | Avitide LLC | Affinity agents |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| WO2000060070A1 (en) * | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP2641919A3 (en) * | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
| BRPI0920749A8 (pt) * | 2008-10-02 | 2017-12-12 | Emergent Product Dev Seattle | Proteínas de ligação de antagonista multialvo cd86 |
| US20120064064A1 (en) * | 2009-05-28 | 2012-03-15 | Thil Dinuk Batuwangala | Antigen-binding proteins |
| US20120076787A1 (en) | 2009-05-28 | 2012-03-29 | Peter Adamson | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye |
| US20190338013A1 (en) * | 2016-02-26 | 2019-11-07 | Imunexus Pty Ltd | Multi-Specific Molecules |
-
2017
- 2017-02-27 US US16/079,949 patent/US20190338013A1/en not_active Abandoned
- 2017-02-27 JP JP2018563747A patent/JP7536424B2/ja active Active
- 2017-02-27 EP EP17755659.4A patent/EP3419667A4/en active Pending
- 2017-02-27 CN CN201780024999.5A patent/CN109310766A/zh active Pending
- 2017-02-27 WO PCT/AU2017/050168 patent/WO2017143406A1/en not_active Ceased
- 2017-02-27 AU AU2017222700A patent/AU2017222700B2/en active Active
- 2017-03-01 TW TW106106646A patent/TW201734037A/zh unknown
-
2019
- 2019-01-02 AU AU2019200005A patent/AU2019200005A1/en not_active Abandoned
-
2020
- 2020-06-22 US US16/946,451 patent/US20210040177A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,935 patent/US11345736B2/en active Active
-
2022
- 2022-05-11 JP JP2022078237A patent/JP2022105574A/ja active Pending
-
2023
- 2023-08-28 US US18/239,052 patent/US20240182542A1/en active Pending
- 2023-12-26 JP JP2023219531A patent/JP2024026531A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510812A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| JP2020519643A5 (enExample) | ||
| JP2017184723A5 (enExample) | ||
| JP2019515646A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| JP2015146822A5 (enExample) | ||
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| JP2018502050A5 (enExample) | ||
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2016053091A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2017176174A5 (enExample) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2014518883A5 (enExample) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| JP2019506841A5 (enExample) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2017536341A5 (enExample) |